Abbott Vascular On Track For 60% Growth In 2007
This article was originally published in The Gray Sheet
Executive Summary
Abbott's vascular business is on target to achieve growth of "at least 60%" this year following a strong first quarter that saw continued success of the firm's Xience V everolimus-eluting coronary stent outside of the United States, the company says
You may also be interested in...
Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC
Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA
Abbott Sells IVD, Point-Of-Care Diagnostics To GE For $8.13 Bil.
With GE's $8.13 billion cash purchase of Abbott Laboratories' core in vitro diagnostics unit Jan. 18, the corporate giant is betting it can accelerate growth in a business still recovering from protracted regulatory challenges in the U.S
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.